Cargando…

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

BACKGROUND: Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More than one...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seymour, John F., Döhner, Hartmut, Butrym, Aleksandra, Wierzbowska, Agnieszka, Selleslag, Dominik, Jang, Jun Ho, Kumar, Rajat, Cavenagh, James, Schuh, Andre C., Candoni, Anna, Récher, Christian, Sandhu, Irwindeep, del Castillo, Teresa Bernal, Al-Ali, Haifa Kathrin, Falantes, Jose, Stone, Richard M., Minden, Mark D., Weaver, Jerry, Songer, Steve, Beach, C. L., Dombret, Hervé
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731212/ https://www.ncbi.nlm.nih.gov/pubmed/29241450 http://dx.doi.org/10.1186/s12885-017-3803-6

Ejemplares similares

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
por: Döhner, Hartmut, et al.
Publicado: (2018)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
por: Wei, Andrew H., et al.
Publicado: (2023)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities()
por: Dennis, M., et al.
Publicado: (2013)

Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemia
por: Butrym, Aleksandra, et al.
Publicado: (2016)

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
por: Pleyer, Lisa, et al.
Publicado: (2017)

P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
por: Döhner, Hartmut, et al.
Publicado: (2023)

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
por: Ravandi, Farhad, et al.
Publicado: (2021)

Azacitidine in outpatient treatment – single center experience
por: Rybka, Justyna, et al.
Publicado: (2016)

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia
por: Romano, Alessandra, et al.
Publicado: (2017)

Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
por: Fenaux, P, et al.
Publicado: (2008)

Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting
por: Nakaya, Aya, et al.
Publicado: (2020)

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
por: Roboz, Gail J, et al.
Publicado: (2016)

Unusual CD34 positivity in acute myeloid leukaemia with myelodysplasia‐related changes with megakaryoblastic differentiation
por: Avenoso, Daniele, et al.
Publicado: (2021)

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial
por: Roboz, Gail J., et al.
Publicado: (2021)

Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options
por: Lang, Fabian, et al.
Publicado: (2017)

Solving the Mystery of Myelodysplasia
por: Radich, Jerald
Publicado: (2008)

Temozolomide-Induced Myelodysplasia
por: Natelson, Ethan A., et al.
Publicado: (2010)

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
por: Pratz, Keith W., et al.
Publicado: (2022)

Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation
por: Nakamura, Yukinori, et al.
Publicado: (2017)

FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
por: Asai-Nishishita, Ai, et al.
Publicado: (2023)

Antineutrophil cytoplasmic antibodies in myelodysplasia.
por: Hull, D. R., et al.
Publicado: (1996)

Bone Marrow Immunity and Myelodysplasia
por: Lambert, Claude, et al.
Publicado: (2016)

Acquired spherocytosis in the setting of myelodysplasia
por: Karlsson, Linda Katharina, et al.
Publicado: (2022)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2018)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

New Insights on Iron Study in Myelodysplasia
por: El Husseiny, Noha M., et al.
Publicado: (2014)

Is Myelodysplasia a Consequence of Normal Aging?
por: Heibl, Sonja, et al.
Publicado: (2021)

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
por: Pollyea, Daniel A., et al.
Publicado: (2022)

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
por: Zeidan, Amer M., et al.
Publicado: (2022)

Relationship between Altered miRNA Expression and DNA Methylation of the DLK1-DIO3 Region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes
por: Merkerova, Michaela Dostalova, et al.
Publicado: (2018)

Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog
por: Natelson, Ethan A., et al.
Publicado: (2013)

Myelodysplasia is in the niche: novel concepts and emerging therapies
por: Bulycheva, E, et al.
Publicado: (2015)

Myelodysplasia and Mast Cell Leukemia with t(9;22)
por: Lago, Kathryn J., et al.
Publicado: (2017)

Methotrexate-induced myelodysplasia mimicking myelodysplastic syndrome
por: Kawase, Yuuki, et al.
Publicado: (2018)

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms
por: Aujla, Amandeep, et al.
Publicado: (2018)

Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease
por: Veiga, Camilla Bertuzzo, et al.
Publicado: (2021)

Copper and Zinc Feud: Is This Myelodysplasia or Myelodysplastic Syndrome?
por: Kumar, Manoj, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_597ass802r3cgvhd2on0le7hpl